SCM
NAGE

Silver Capital Management’s Niagen Bioscience NAGE Stock Holding History

Silver Capital Management’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-13,562
Closed -$45K – 55
2016
Q4 		$45K Sell
13,562
-129,453
-91% -$352K 0.21% 40
2016
Q3 		$427K Buy
143,015
+44,035
+44% +$162K 1.79% 28
2016
Q2 		$410K Buy
+98,980
New +$468K 1.95% 23

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.63B AUM 38.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NSIM
North Star Investment Management Chicago, Illinois $1.65B AUM 20.56% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Silver Capital Management's NAGE Position: Q1 2017 in Review

Silver Capital Management sold out of Niagen Bioscience (NAGE) in Q1 2017, closing a stake of 13,562 shares — an estimated $45K sold.

Silver Capital Management first reported a position in NAGE in Q2 2016 and held it in 3 quarters. The position peaked at $427K in Q3 2016. 46 funds tracked by Wall St. Rank hold NAGE as of Q1 2017.

  • Silver Capital Management reported no remaining Niagen Bioscience position as of Q1 2017 after selling out during the quarter.
  • Silver Capital Management sold 13,562 Niagen Bioscience shares in Q1 2017, an estimated $45K.
  • Silver Capital Management first reported a position in Niagen Bioscience in Q2 2016 and held it in 3 quarters.
  • Silver Capital Management's Niagen Bioscience position peaked at $427K in Q3 2016.
  • 46 funds tracked by Wall St. Rank held Niagen Bioscience as of Q1 2017.

Based on Silver Capital Management's 13F filing for Q1 2017, filed 10 May 2017.